Evidence map›Paper›PMID 38365988›Full record

ArticleScientific reports2024

Intravenous immunoglobulin for patients with unexplained recurrent implantation failure: a 6-year single center retrospective review of clinical outcomes.

Einav Kadour Peero, Shorooq Banjar, Rabea Khoudja, Shaonie Ton-Leclerc, Coralie Beauchamp, Joanne Benoit, Marc Beltempo, Michael H Dahan, Phil Gold, Isaac Jacques Kadoch and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 3 countries.

Einav Kadour PeeroDepartment of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Bnai-Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Shorooq BanjarDivision of Clinical Immunology and Allergy, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Rabea KhoudjaDivision of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
Shaonie Ton-LeclercDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Coralie BeauchampOvo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
Joanne BenoitOvo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
Marc BeltempoDivision of Neonatology, Montreal Children's Hospital - McGill University Health Centre, Montreal, QC, Canada.
Michael H DahanDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, QC, Canada.
Phil GoldDepartment of Allergy and Immunology, Montreal General Hospital, 1650 Cedar Ave. A6-123, Montreal, QC, H3G 1A4, Canada.
Isaac Jacques KadochOvo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
Wael JamalClinique OVO, 8000 boulevard Décarie, Montréal, QC, H4P 2S4, Canada.
Carl LaskinTRIO Fertility, 655 Bay St, Toronto, ON, M5G 2K4, Canada.
Neal MahutteThe Montreal Fertility Centre, 5252 de Maisonneuve Blvd West, Suite 220, Montreal, QC, H4A 3S5, Canada.
Simon PhillipsClinique OVO, 8000 boulevard Décarie, Montréal, QC, H4P 2S4, Canada.
Camille SylvestreOvo Clinic, 8000 Boulevard Decarie, Montréal, QC, H4P 2S4, Canada.
Shauna ReinblattDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, QC, Canada.
Bruce D MazerDepartment of Pediatrics, Division of Allergy Immunology and Clinical Dermatology, Montreal Children's Hospital, McGill University, Montréal, QC, Canada.
William BuckettDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montréal, QC, Canada.
Genevieve GenestDivision of Clinical Immunology and Allergy, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada. genevieve.genest@mail.mcgill.ca.
McGill University Health Centre · CAUniversité de Montréal · CACegep Edouard Montpetit · CACollège de Maisonneuve · CACReATe Fertility Centre · CAKing Abdulaziz University · SAMontreal General Hospital · CAOttawa Fertility Centre · CAQueen's University · CATechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of intravenous immunoglobulin (IVIg) for patients with unexplained recurrent implantation failure (uRIF) remains debated. We retrospectively analysed outcomes of uRIF patients treated with IVIg compared to a separate control uRIF cohort within our center (01/2014-12/2021). Primary outcomes included live birth, miscarriage, or transfer failure. We documented IVIg side effects and maternal/fetal outcomes. Logistic regression analysis was used to assess for association of IVIg exposure with outcomes and adjust for confounders. The study included 143 patients, with a 2:1 ratio of controls to patients receiving IVIg treatment. Patient characteristics were similar between groups. There was higher live birth rate (LBR) in patients receiving IVIg (32/49; 65.3%) compared to controls (32/94; 34%); p < 0.001). When stratifying patients into moderate and severe uRIF (respectively 3-4 and [Formula: see text] 5 previous good quality blastocyst transfer failures), only patients with severe uRIF benefited from IVIg (LBR (20/29 (69%) versus 5/25 (20%) for controls, p = 0.0004). In the logistic regression analysis, IVIg was associated with higher odds of live birth (OR 3.64; 95% CI 1.78-7.67; p = 0.0004). There were no serious adverse events with IVIg. IVIg can be considered in well selected patients with [Formula: see text] 5 previous unexplained, high quality blastocyst transfer failures. A randomized controlled trial is needed to confirm these findings.

Indexed as

Immunoglobulins, IntravenousBirth RateFemaleHumansLive BirthPregnancyRetrospective StudiesImmunoglobulins, IntravenousImmune-mediated recurrent implantation failureIntravenous immunoglobulinReproductive immunologyUnexplained recurrent implantation failure

Identifiers

PMID38365988
PMCPMC10873418
OpenAlexW4391882403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.